ClinicalTrials.gg
RecruitingNCT06550310NUTRICO-IBDUpdated Feb 19, 2026

Nutrition and Clinical Outcomes in IBD

An observational study in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Barts & The London NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Barts & The London NHS Trust · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom — 20 open to participants now, 28 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United Kingdom.

Planned enrollment
16th of 42
300 · median 215
Started
2024
with 9 others
Observational
42 of 112
9 open now
Primary completion
2028-05
later than 21 of 27 live
Registered
103rd of 112
by date

Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, this one is the 16th largest by planned enrollment of the 42 observational ones that give a count, is one of 10 that started in 2024, is one of 42 observational ones, reaches primary completion later than 21 of the 27 other live ones, and was the 103rd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

20 of the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this observational study is to demonstrate that nutritional status and body composition have an impact on clinical outcomes in inflammatory bowel disease (IBD).

The main objectives are:

  1. To compare the detection rates of undernutrition between a range of nutritional screening tools, physiological measures and assessment tools amongst patients with different IBD phenotypes
  2. To correlate nutritional status, nutritional biomarkers and body composition with clinical outcomes in patients with IBD treated with advanced medical therapy or surgery
  3. To determine a potential relationship between radiological muscle mass measurements and clinical outcomes in patients with IBD treated with advanced medical therapy or surgery

Participants will undergo an assessment at pre-treatment baseline and then again at their scheduled follow-up. This is a non-interventional study and participants will not be required to have any invasive tests or hospital visits beyond that of standard clinical care.

Read the detailed description

Background and Rationale:

Inflammatory bowel disease (IBD) comprises Crohn's disease (CD) and ulcerative colitis (UC). It affects nearly 400,000 people in the United Kingdom (UK) and the global prevalence is rising. Many patients suffer an impaired quality of life. Whilst advanced medical therapies are being used more often, the lifetime risk of surgery is as high as 70%. Unfortunately, loss of response to medical therapies and post-operative complications remain major clinical challenges. Risk factors for adverse treatment outcomes include disease duration, emergency surgery and undernutrition. Not only is undernutrition a risk factor for adverse clinical outcomes, it is present in up to 36% of patients with IBD. Crucially, unlike other risk factors, it is also modifiable with cheap and safe interventions. It therefore presents an ideal opportunity for intervention. Despite this, current methods of detecting undernutrition in IBD are unfit for purpose.

Body composition (BC) analysis is emerging as a highly clinically relevant physiological marker in IBD. Skeletal muscle loss with functional impairment (sarcopenia) in IBD patients is associated with a range of outcomes including disease flares, hospitalisation, need for surgery and need for ICU admissions. Radiological measurement of skeletal muscle index (SMI) at the level of the 3rd lumbar vertebra is objective and reproducible. Validated software designed specifically for this purpose (Slice-o-Matic [Tomovision, Canada]) can be used on CT/MRI scans which are often performed as part of standard IBD care. However, despite this, BC analysis by any method is not performed in routine clinical practice. The most commonly used physiological markers in the UK remain weight and body mass index (BMI), which do not provide any measure of BC.

Overall, there remains uncertainty over which nutritional tools should be used in patients with IBD. Most studies have been small, retrospective and heterogenous. No study has performed a comparative analysis of more than three measurements in the same patient cohort. Evidence of the ability of widely used nutritional screening tools to identify IBD patients most at risk of adverse clinical outcomes is lacking. Finally, there is little data describing the performance of different tools and measures according to disease phenotype and disease activity. This study proposes to meet this knowledge gap by comparing a range of nutritional tools in a large, prospective, well-phenotyped IBD cohort.

Study design:

Eligible patients will be identified from dedicated IBD multi-disciplinary weekly meetings, IBD clinic, medical infusion suites and the medical records. The clinical team will be aware of the study and can also flag potential eligible patients to the investigators. Participants will be contacted or approached directly in clinic or via telephone.

This will be a prospective, non-interventional study performed at Barts Health National Health Service (NHS) Trust over 4 years. For patients treated with advanced medical therapies, the entire prospective dataset will be collected at a pre-treatment baseline (within 4 weeks before treatment) and at weeks 14 and 52 after therapy commencement. For patients undergoing surgery, data will be collected at a pre-operative baseline (within 4 weeks before surgery) and at 3 months post-operatively. Data relating to dietetic input and artificial nutritional support will be included. The following outcomes from medical therapy will be collected at weeks 14 and 52: clinical response, clinical and biochemical remission, corticosteroid use, therapy switch, IBD-surgery. The following surgical outcomes will be collected: length of post-operative stay, formation of unplanned stoma, 30-day complication rate, 30-day complication grade (defined by the Clavien-Dindo scale) and 90-day readmission rate. Participants will then be followed-up longitudinally over the aforementioned defined timepoints. Muscle mass measurements will be performed by exporting CT/MRI image slices at the level of the third vertebra from Trust computers and using Slice-O-Matic software to measure skeletal muscle indices (SMI). Additionally, we will access de-identified CT/MRI scans from 946 well-phenotyped patients who have undergone IBD surgery collected by the national UK IBD Bioresource and made available via the Gut Reaction initiative hosted by the National Institute for Health and Care Research (NIHR). Post-operative outcome data will also be available, enabling this to be used as an external validation cohort to the primary surgical dataset. Within the internal cohort, handgrip strength and timed up and go test (TUG) or gait speed will be performed prospectively at scheduled visits, to assess muscle strength and physical performance respectively. All nutritional parameters collected will be correlated with clinical outcomes.

The clinical data that will be collected is outlined below:

Demographics: age, gender, ethnicity, comorbidities, smoking status, postcode IBD phenotype: diagnosis, duration, disease location and behaviour (CD), disease extent (UC) IBD treatment: current IBD therapy (>3 months), previous IBD therapy, previous IBD-related surgery IBD activity: Harvey Bradshaw Index (HBI) or partial Mayo scores, C-reactive protein (CRP), faecal calprotectin Nutritional screening tools: Malnutrition Universal Screening Tool (MUST), Nutrition Risk Screening Tool-2002 (NRS-2002), Malnutrition Inflammation Risk Tool (MIRT) Nutritional assessment tools: Subjective Global Assessment (SGA), Global Leadership Initiative on Malnutrition (GLIM) criteria Weight, height, BMI, anthropometry (waist circumference, mid-upper arm circumference, triceps skinfold thickness, mid-arm muscle circumference) Handgrip strength Timed up and go test (TUG) or gait speed Bioelectrical impedance analysis, including skeletal muscle mass (kg), body fat (%) and visceral adiposity (kg) Blood tests: Haemoglobin, folate, ferritin, B12, vitamin D, zinc, copper, selenium Dietetics: dietetic review, special diets, presence and type of artificial nutritional support Food intake (24-hour food diaries) Food frequency questionnaire Food-related quality of life questionnaire Skeletal muscle index

The end of recruitment will be month 18 for the medical arm and month 27 for the surgical arm, to allow sufficient time for follow-up and data analysis. The End of Study will be defined as the conclusion of follow-up monitoring, data analysis and write-up at month 36.

Analysis:

Descriptive statistics will be taken at baseline for both medical and surgical cohorts. These exploratory variables will be measured at the three timepoints (as outlined above) to compare if any statistically significant difference is present. Statistical significance will be considered if a threshold of p=0.05. One-way repeated measures analysis of variance (ANOVA) will be performed for both groups.

Further sub-group analysis to determine correlations between the exploratory variables and outcomes will be performed using multi-linear and binary logistic regression. Standard demographical analysis will be collected and further sub-group analysis based on ethnicity may be performed.

Ethical approval has been obtained from the Health Research Authority.

This study is sponsored by Barts Health NHS Trust.

There are no conflicts of interest.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Ulcerative Colitis
  • Malnutrition
  • Sarcopenia

Keywords

  • Body composition
  • Nutritional status
  • Nutritional markers
  • Nutritional screening tools
  • Nutritional assessment
  • Sarcopenia
  • Radiological muscle mass
  • Inflammatory bowel disease
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults (>16) with a diagnosis of inflammatory bowel disease (IBD) attending a tertiary IBD centre who are undergoing a new treatment or change in treatment, or an operation for their condition

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) starting a new advanced medical therapy
  • Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) undergoing an IBD-related surgery
  • Age >16
  • Patients able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Patients below the age of 16
  • Patients who cannot provide
  • Patients with a cardiac pacemaker or internal defibrillator
  • Patients with active cancer and other disorders associated with severe cachexia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Medical treatment group

    Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) starting a new advanced medical therapy (e.g. biologic or small molecule)

  • Surgical treatment group

    Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) undergoing an IBD-related surgery

06

What researchers measure

Primary outcomes

  1. Correlation of nutritional parameters (at baseline and during treatment) with pre-defined clinical outcomes in patients undergoing advanced medical therapy (at 14 and 52 weeks).

    Clinical outcomes are as follows clinical response, clinical and biochemical remission, corticosteroid use, therapy switch or IBD related-surgery. Clinical response in UC is defined as a ≥2-point and ≥30% decrease from baseline in partial Mayo score and a ≥1-point decrease from baseline in rectal bleeding sub-score or an absolute rectal bleeding sub-score ≤1. Clinical response in CD is defined as ≥ 3 points decrease of HBI score. Clinical remission is defined as a partial Mayo score of 0-1 in UC or HBI of ≤4 in CD. Biochemical remission is defined as faecal calprotectin \<200μg/mg and CRP ≤5mg/L.

    Time frame: 14 and 52 weeks

  2. Correlation of nutritional parameters (at baseline and during treatment) with pre-defined clinical outcomes in patients undergoing IBD-related surgery (at 30 and 90 days).

    Clinical outcomes are defined as length of post-operative stay, formation of unplanned stoma, 30-day complication rate, 30-day complication grade (defined by the Clavien-Dindo scale) and 90-day readmission rate.

    Time frame: 30 and 90 days

Secondary outcomes

  1. Correlation of currently used radiological muscle mass thresholds with pre-defined clinical outcomes in patients undergoing advanced medical therapy (at 14 and 52 weeks).

    Clinical outcomes are as follows clinical response, clinical and biochemical remission, corticosteroid use, therapy switch or IBD related-surgery. Clinical response in UC is defined as a ≥2-point and ≥30% decrease from baseline in partial Mayo score and a ≥1-point decrease from baseline in rectal bleeding sub-score or an absolute rectal bleeding sub-score ≤1. Clinical response in CD is defined as ≥ 3 points decrease of HBI score. Clinical remission is defined as a partial Mayo score of 0-1 in UC or HBI of ≤4 in CD. Biochemical remission is defined as faecal calprotectin \<200μg/mg and CRP ≤5mg/L.

    Time frame: 14 and 52 weeks

  2. Correlation of currently used radiological muscle mass thresholds with pre-defined clinical outcomes in patients undergoing advanced IBD-related surgery (at 30 and 90 days).

    Clinical outcomes are defined as length of post-operative stay, formation of unplanned stoma, 30-day complication rate, 30-day complication grade (defined by the Clavien-Dindo scale) and 90-day readmission rate.

    Time frame: 30 and 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4. Epub 2019 Oct 21. PubMed 31648971 ↗
  • Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I. Inflamm Bowel Dis. 2018 Mar 19;24(4):742-751. doi: 10.1093/ibd/izx100. PubMed 29562277 ↗
  • Lewis RT, Maron DJ. Efficacy and complications of surgery for Crohn's disease. Gastroenterol Hepatol (N Y). 2010 Sep;6(9):587-96. PubMed 21088749 ↗
  • Gklavas A, Dellaportas D, Papaconstantinou I. Risk factors for postoperative recurrence of Crohn's disease with emphasis on surgical predictors. Ann Gastroenterol. 2017;30(6):598-612. doi: 10.20524/aog.2017.0195. Epub 2017 Sep 26. PubMed 29118554 ↗
  • Ma C, Moran GW, Benchimol EI, Targownik LE, Heitman SJ, Hubbard JN, Seow CH, Novak KL, Ghosh S, Panaccione R, Kaplan GG. Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. Am J Gastroenterol. 2017 Dec;112(12):1840-1848. doi: 10.1038/ajg.2017.394. Epub 2017 Oct 31. PubMed 29087396 ↗
  • Ananthakrishnan AN, Shi HY, Tang W, Law CC, Sung JJ, Chan FK, Ng SC. Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. J Crohns Colitis. 2016 Oct;10(10):1224-36. doi: 10.1093/ecco-jcc/jjw054. Epub 2016 Feb 29. PubMed 26928965 ↗
  • Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis. 2008 Aug;14(8):1105-11. doi: 10.1002/ibd.20429. PubMed 18302272 ↗
  • Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A novel risk score to stratify severity of Crohn's disease hospitalizations. Am J Gastroenterol. 2010 Aug;105(8):1799-807. doi: 10.1038/ajg.2010.105. Epub 2010 Mar 9. PubMed 20216534 ↗
  • Ciocirlan M, Ciocirlan M, Iacob R, Tantau A, Gheorghe L, Gheorghe C, Dobru D, Constantinescu G, Cijevschi C, Trifan A, Goldis A, Diculescu M. Malnutrition Prevalence in Newly Diagnosed Patients with Inflammatory Bowel Disease - Data from the National Romanian Database. J Gastrointestin Liver Dis. 2019 Jun 1;28:163-168. doi: 10.15403/jgld-176. PubMed 31204412 ↗
  • Casanova MJ, Chaparro M, Molina B, Merino O, Batanero R, Duenas-Sadornil C, Robledo P, Garcia-Albert AM, Gomez-Sanchez MB, Calvet X, Trallero MDR, Montoro M, Vazquez I, Charro M, Barragan A, Martinez-Cerezo F, Megias-Rangil I, Huguet JM, Marti-Bonmati E, Calvo M, Campdera M, Munoz-Vicente M, Merchante A, Avila AD, Serrano-Aguayo P, De Francisco R, Hervias D, Bujanda L, Rodriguez GE, Castro-Laria L, Barreiro-de Acosta M, Van Domselaar M, Ramirez de la Piscina P, Santos-Fernandez J, Algaba A, Torra S, Pozzati L, Lopez-Serrano P, Arribas MDR, Rincon ML, Pelaez AC, Castro E, Garcia-Herola A, Santander C, Hernandez-Alonso M, Martin-Noguerol E, Gomez-Lozano M, Monedero T, Villoria A, Figuerola A, Castano-Garcia A, Banales JM, Diaz-Hernandez L, Arguelles-Arias F, Lopez-Diaz J, Perez-Martinez I, Garcia-Talavera N, Nuevo-Siguairo OK, Riestra S, Gisbert JP. Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2017 Dec 4;11(12):1430-1439. doi: 10.1093/ecco-jcc/jjx102. PubMed 28981652 ↗
  • Bamba S, Sasaki M, Takaoka A, Takahashi K, Imaeda H, Nishida A, Inatomi O, Sugimoto M, Andoh A. Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn's disease. PLoS One. 2017 Jun 23;12(6):e0180036. doi: 10.1371/journal.pone.0180036. eCollection 2017. PubMed 28644887 ↗
  • Zhang T, Cao L, Cao T, Yang J, Gong J, Zhu W, Li N, Li J. Prevalence of Sarcopenia and Its Impact on Postoperative Outcome in Patients With Crohn's Disease Undergoing Bowel Resection. JPEN J Parenter Enteral Nutr. 2017 May;41(4):592-600. doi: 10.1177/0148607115612054. Epub 2015 Oct 15. PubMed 26471990 ↗
  • Pedersen M, Cromwell J, Nau P. Sarcopenia is a Predictor of Surgical Morbidity in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Oct;23(10):1867-1872. doi: 10.1097/MIB.0000000000001166. PubMed 28604415 ↗
  • Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, Makary M, Hirose K, Edil B, Choti MA, Herman J, Cameron JL, Wolfgang CL, Pawlik TM. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012 Aug;16(8):1478-86. doi: 10.1007/s11605-012-1923-5. Epub 2012 Jun 13. PubMed 22692586 ↗
  • Lomer MC, Gourgey R, Whelan K. Current practice in relation to nutritional assessment and dietary management of enteral nutrition in adults with Crohn's disease. J Hum Nutr Diet. 2014 Apr;27 Suppl 2:28-35. doi: 10.1111/jhn.12133. Epub 2013 Jun 13. PubMed 23763616 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2028, 43 months after the start.

Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 43 months is above that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2024
First posted
Aug 13, 2024
StartActual
Oct 24, 2024
Primary completionEst.
May 2028
CompletionEst.
Dec 2028
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06550310
Responsible party
Sponsor
First posted
Aug 13, 2024
Start date
Oct 24, 2024
Primary completion
May 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 19, 2026

Study contacts

Sarah Faloon, MBChB
Contact
sarah.faloon@nhs.net
07713444631
Shameer Mehta, MD
Contact
shameer.mehta@nhs.net
020 3594 3500
Shameer Mehta, MD
principal investigator · Barts & The London NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion